

Prof. Yibin Wang's lab, UCLA – Ramino-Bio LTD. visit

Including Technology Transfer, July 15-16th, 2019

Ramino's aim is to develop a small-molecule compound (SMC) that enhances the BCAA catabolism of subjects with cardiometabolic diseases by targeting BCKDK (=BDK).

Purpose of visit: Introduction with Prof. Yibin Wang, his colleagues, his lab, as well as UCLA Technology Development group members, UCLA facilities, Discussion with other project-related members, and Perform technology transfer from Lab to Ramino-Bio including knowledge and data transfer, overview and assessment for studies and planned development program.

Attendees

University of California at Los Angeles: Prof. Yibin Wang, Principle Investigator

C.G., Ph.D., Wang's lab

A.N., CEO, and president UCLA Development Group

E.W., Ph.D, BD Technology Development Group

D.H., MD, Director UCLA Human Nutrition/Diabetes program

O.S., MD, PhD Mitochondria Core and Metabolism Theme director

A.N., MD, Cardiovascular Center Heart Failure director

Shanghai Jiao Tong University

Dr. H.S., Principal Investigator

University of Texas Southwestern

Prof. D.C., principal investigator.

Dr. R.M.W., Associate Professor, D.C.'s lab

FutuRx / Ramino-Bio LTD.

L.K., CTO, Ph.D.

Dorit Cohen-Carmon, CSO, Ph.D.

AGENDA

Monday, July 15th

- | | |
|---------------|---|
| 09:00 – 09:15 | <u>Introduction</u>
Wang's and C.D.'s Lab staff with Ramino-Bio/ FutuRx |
| 09:15 – 10:00 | <u>Ramino-Bio Development Plan – Presentation and Q&A</u>
Dorit Cohen-Carmon
Overview including Y-1 milestones, assays to be developed, Hit identification strategies |
| 10:00 – 11:15 | <u>Wang's lab current BCAA studies – Presentation and Q&A</u>
Dr. H.S. and C.G from Wang's group on BCAA research
Dr. Y.W. on Other Research Projects |
| 11:15 – 11:30 | Break |
| 11:30 – 11:45 | <u>Lab and Animal facility tour including HMDP strains.</u> |
| 12:00 – 13:15 | <u>Lunch</u>
FutuRx / Ramino & lab members |
| 13:15 – 13:45 | Break |
| 14:30 – 15:15 | Director UCLA Human Nutrition/Diabetes program – clinical opportunity in cardiometabolic diseases
Dr. Z.L., Rehab Center |
| 15:30 – 16:00 | Mitochondria Core and Metabolism Theme director – mechanisms of action in treating cardiometabolic diseases
Dr. O.S., CHS |
| 16:15 – 16:45 | Heart failure director – Clinical opportunity of treating cardiometabolic diseases
TBD (to be confirmed) |

Tuesday, July 16th

09:00 – 12:00

Wang's lab tech transfer to Ramino-Bio

Tech Transfer issues (see table below)

1. Delivery of in-vitro raw data, protocols, experiments & reports
2. Reagents and chemicals handling, storage, processing
3. Delivery of In-vivo protocols and results
4. Discussions with relevant scientists per (1-3).

12:15 – 13:15

Lunch with Technology business group members

13:30 – 15:30

Tech Transfer – continuation.

15:45 – 16:30

A 1:1 meeting Ramino-Bio with Yibin Wang and Dr. H.S.

Discussion on future Lab studies involving Ramino's milestones, especially in-vivo models. Responsibilities, facilities, protocols, materials, specifications, documentation, results, analysis – to be continued in a future meeting.

16:30 – 17:15

Summary, next steps, greetings and farewell

Tech Transfer detailed plan

It is very important to get as much information as possible for failed attempts & directions as for successes. These data are highly valuable in tech transfer from scientists who conducted the studies.

Technology Transfer from the Yibin's Lab to Ramino-Bio will include:

Task #	Task	Execution
1	Transfer In-vitro protocols, assay qualification and knowledge	Transfer knowledge, protocol guidance, methods, results, enzymatic (biochemical) and cell-based assays, cell lines, readout, including BCAA/ BCKA levels quantification in plasma and tissues.
2	Materials from the Lab to Ramino-Bio	Reagents, materials and cell lines used for in-vitro and n-vivo assays, notes for special handling, storage and preparation.
3	in-vivo results, protocols, workplan	Transfer knowledge, ethical requests, protocol guidance, disease models, results, adverse effects, changes needed for company (e.g. metabolic disease mouse models), lessons learned.
4	Studies in Lab per workplan	Discuss future plan studies together. Based on results and discussion with scientists & clinicians.